EE342 Evaluation of the Cost-Effectiveness of Dapagliflozin Vs. Empagliflozin for Treating Heart Failure with Reduced Ejection Fraction in the United States
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.643
https://www.valueinhealthjournal.com/article/S1098-3015(23)00743-X/fulltext
Title :
EE342 Evaluation of the Cost-Effectiveness of Dapagliflozin Vs. Empagliflozin for Treating Heart Failure with Reduced Ejection Fraction in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00743-X&doi=10.1016/j.jval.2023.03.643
First page :
Section Title :
Open access? :
No
Section Order :
10127